vs
Side-by-side financial comparison of Maase Inc. (MAAS) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
Maase Inc. is the larger business by last-quarter revenue ($9.9M vs $9.3M, roughly 1.1× STRATA Skin Sciences, Inc.). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-18.3M).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
MAAS vs SSKN — Head-to-Head
Income Statement — Q2 FY2023 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.9M | $9.3M |
| Net Profit | — | $58.0K |
| Gross Margin | 78.7% | 61.8% |
| Operating Margin | -55.9% | 5.3% |
| Net Margin | — | 0.6% |
| Revenue YoY | — | -3.0% |
| Net Profit YoY | — | 101.3% |
| EPS (diluted) | — | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $9.3M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | — | $7.7M | ||
| Q1 25 | — | $6.8M | ||
| Q4 24 | — | $9.6M | ||
| Q3 24 | — | $8.8M | ||
| Q2 24 | — | $8.4M | ||
| Q1 24 | — | $6.8M |
| Q4 25 | — | $58.0K | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-2.6M | ||
| Q1 25 | — | $-2.1M | ||
| Q4 24 | — | $-4.6M | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | — | $-91.0K | ||
| Q1 24 | — | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | -16.9% | ||
| Q2 25 | — | -30.1% | ||
| Q1 25 | — | -25.0% | ||
| Q4 24 | — | -44.7% | ||
| Q3 24 | — | -18.2% | ||
| Q2 24 | — | -5.7% | ||
| Q1 24 | — | -42.7% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | -23.4% | ||
| Q2 25 | — | -33.6% | ||
| Q1 25 | — | -31.2% | ||
| Q4 24 | — | -47.6% | ||
| Q3 24 | — | -23.6% | ||
| Q2 24 | — | -1.1% | ||
| Q1 24 | — | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $-0.62 | ||
| Q1 25 | — | $-0.51 | ||
| Q4 24 | — | $-2.01 | ||
| Q3 24 | — | $-0.51 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.9M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $31.6M | $2.9M |
| Total Assets | $47.0M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $6.5M | ||
| Q4 24 | — | $7.3M | ||
| Q3 24 | — | $7.1M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $1.3M | ||
| Q2 25 | — | $532.0K | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | — | $9.4M |
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $30.7M | ||
| Q2 25 | — | $29.5M | ||
| Q1 25 | — | $33.0M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.2M | $-239.0K |
| Free Cash FlowOCF − Capex | $-18.3M | $-551.0K |
| FCF MarginFCF / Revenue | -184.4% | -5.9% |
| Capex IntensityCapex / Revenue | 1.0% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-239.0K | ||
| Q3 25 | — | $-64.0K | ||
| Q2 25 | — | $-1.9M | ||
| Q1 25 | — | $-550.0K | ||
| Q4 24 | — | $703.0K | ||
| Q3 24 | — | $-302.0K | ||
| Q2 24 | — | $591.0K | ||
| Q1 24 | — | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | — | $199.0K | ||
| Q3 24 | — | $-364.0K | ||
| Q2 24 | — | $246.0K | ||
| Q1 24 | — | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | -4.1% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 5.3% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.1% | ||
| Q1 24 | — | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAAS
| Wealth management | $7.8M | 78% |
| Insurance consulting | $1.0M | 10% |
| Other | $975.0K | 10% |
| Asset management | $168.0K | 2% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
